Skip to content

Study · Animal study (in vivo) · rat · 2021

6 results

Stable Gastric Pentadecapeptide BPC 157 Therapy of Rat Glaucoma.

Kralj T, Kokot A, Zlatar M, Masnec S, Kasnik Kovac K, Milkovic Perisa M, Batelja Vuletic L, Giljanovic A, Strbe S, Sikiric S, Balog S, Sontacchi B and 7 more

Show all authors

Sontacchi D, Buljan M, Lovric E, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P

Biomedicines31 Dec 2021Cited by 24 (Europe PMC)

PMID35052769 (opens in a new tab)PMCIDPMC8773185 (opens in a new tab)DOI10.3390/biomedicines10010089 (opens in a new tab)PepBankPUB-35052769
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats. If not upgraded, one episcleral vein is regularly unable to acquire and take over the whole function, and glaucoma-like features persist. Recently, the rapid upgrading of the collateral pathways by a stable gastric pentadecapeptide BPC 157 has cured many severe syndromes induced by permanent occlusion of major vessels, veins and/or arteries, peripherally and centrally. In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery). The daily regimen of BPC 157 (0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg) was administered locally as drops in each eye, intraperitoneally (last application at 24 h before sacrifice) or per-orally in drinking water (0.16 µg/mL, 0.16 ng/mL, 12 mL/rat until the sacrifice, first application being intragastric). Consequently, all BPC 157 regimens immediately normalized intraocular pressure. BPC 157-treated rats exhibited normal pupil diameter, microscopically well-preserved ganglion cells and optic nerve presentation, normal fundus presentation, normal retinal and choroidal blood vessel presentation and normal optic nerve presentation. As leading symptoms, increased intraocular pressure and mydriasis, as well as degeneration of retinal ganglion cells, optic nerve head excavation and reduction in optic nerve thickness, generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels and severe optic nerve disc atrophy were all counteracted. In conclusion, we claim that the reversal of the episcleral veins cauterization glaucoma appeared as a consequence of the BPC 157 therapy of the vessel occlusion-induced perilous syndrome.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, all BPC‑157 regimens immediately normalized intraocular pressure.

    In plain wordsIn rats with a glaucoma model, every BPC‑157 regimen brought eye pressure back to normal right away.

    Peptide
    BPC-157
    Outcome
    DecreaseIntraocular pressure
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Vision and retina · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    Consequently, all BPC 157 regimens immediately normalized intraocular pressure.
    2 context sentences
    Summary · context
    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats.
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, BPC‑157-treated rats had normal pupil diameter, and mydriasis was counteracted.

    In plain wordsIn rats with a glaucoma model, BPC‑157 treatment was followed by normal pupil size.

    Peptide
    BPC-157
    Outcome
    DecreasePupil diameter (mydriasis)
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Vision and retina · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    BPC 157-treated rats exhibited normal pupil diameter
    3 context sentences
    Summary · context
    mydriasis
    Summary · context
    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats.
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, BPC‑157-treated rats had microscopically well-preserved ganglion cells, and ganglion cell degeneration was counteracted.

    In plain wordsIn rats with a glaucoma model, BPC‑157 treatment was followed by well-preserved retinal nerve cells.

    Peptide
    BPC-157
    Outcome
    DecreaseRetinal ganglion cell degeneration
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    microscopically well-preserved ganglion cells
    3 context sentences
    Summary · context
    degeneration of retinal ganglion cells
    Summary · context
    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats.
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, BPC‑157 counteracted optic nerve head excavation, reduction in optic nerve thickness and severe optic nerve disc atrophy, with a normal optic nerve presentation.

    In plain wordsIn rats with a glaucoma model, BPC‑157 treatment was followed by a normal-looking optic nerve and less nerve damage.

    Peptide
    BPC-157
    Outcome
    DecreaseOptic nerve (excavation, thickness reduction, disc atrophy)
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    optic nerve head excavation and reduction in optic nerve thickness
    4 context sentences
    Summary · context
    severe optic nerve disc atrophy were all counteracted.
    Summary · context
    and optic nerve presentation, normal fundus presentation, normal retinal and choroidal blood vessel presentation and normal optic nerve presentation.
    Summary · context
    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats.
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, BPC‑157-treated rats had normal retinal and choroidal vessels, and irregular retinal vessels and faint choroidal vessels were counteracted.

    In plain wordsIn rats with a glaucoma model, BPC‑157 treatment was followed by normal-looking blood vessels in the retina and choroid.

    Peptide
    BPC-157
    Outcome
    DecreaseRetinal and choroidal blood vessel presentation
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    normal retinal and choroidal blood vessel presentation
    3 context sentences
    Summary · context
    generalized severe irregularity of retinal vessels, faint presentation of choroidal vessels
    Summary · context
    Cauterization of three episcleral veins (open-angle glaucoma model) induces venous congestion and increases intraocular pressure in rats.
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with episcleral vein cauterization glaucoma, BPC‑157-treated rats had a normal fundus presentation.

    In plain wordsIn rats with a glaucoma model, BPC‑157 treatment was followed by a normal-looking back of the eye.

    Peptide
    BPC-157
    Outcome
    DecreaseFundus presentation
    Study

    ratn: not reported in source

    Episcleral vein cauterization (open-angle glaucoma model)
    Outcome group
    Neuroprotection · Eye
    Studied dose
    0.4 µg/eye, 0.4 ng/eye; 10 µg/kg, 10 ng/kg; 0.16 µg/mL, 0.16 ng/mL in drinking water · eye drops, intraperitoneal, or oral in drinking water · six weeksAs given in this study (rat).

    Source sentences

    Summary
    normal fundus presentation
    1 context sentence
    Summary · context
    In a six-week study, medication was given prophylactically (immediately before glaucoma surgery, i.e., three episcleral veins cauterization) or as curative treatment (starting at 24 h after glaucoma surgery).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.